Addressing Life-Threatening Diseases

Sepsis is the leading cause of death worldwide, affecting 49 million patients and claiming the lives of 11 million people each year. Eliaz Therapeutics aims to keep families together and transform outcomes through targeted innovation.

THE PROBLEM

Sepsis is the #1 Cause of
ICU Death Worldwide

And there are currently no approved, effective therapeutic interventions – yet.

High ICU
Prevalence

Sepsis affects 30-50% of all patients in intensive care units.

The Fatal
Complication

Sepsis-induced Acute Kidney Injury (SA-AKI) doubles mortality rates to over 50%.

Global  
Mortality

Sepsis kills 11 million each year – and the numbers are rising.

Economic  
Burden

Sepsis costs the US healthcare system over $62B annually in direct medical cost alone.

Supportive Care is not Effective Enough

Patients with sepsis face estimated mortality rates of up to 30%, rising to over 60% in critically-ill patients requiring dialysis — yet current treatments are limited to primarily managing symptoms with fluids and antibiotics.

Galectin-3: A Key Driver of Life-Threatening Disease

Galectin-3 is a protein naturally produced by the body in response to injury, but in critical conditions, becomes a "master switch" that drives systemic inflammation and organ failure.

Galectin-3

From Protective to Pathologic

Galectin-3 supports normal immune response, but at elevated levels becomes a driver of uncontrolled inflammation.

Systemic Impact in Sepsis

Sustained activation contributes to vascular damage, organ failure, and rapid clinical deterioration.

Unaddressed Root Cause

Current treatments manage symptoms but do not remove Galectin-3.

Introducing A Different Approach:

The XGAL-3® device

Targeted Removal

Designed to selectively remove Galectin-3

Therapeutic Apheresis

Blood is processed outside the body and returned to circulation

Proprietary Resin

Antibody-based resin engineered to bind Galectin-3

Blood Extraction

Blood enters the apheresis device circuit from the patient via a central line or dialysis access.

Galectin-3 Binding

XGal-3® binds circulating Galectin-3 within the device column.

Filtered Blood Return

Filtered blood returns to the patient with reduced levels of circulating Galectin-3.

Mechanism of Action XGal-3® in Treatment

Broader Technology
Potential

XGal-3® is designed as a platform technology for the selective removal of circulating Galectin-3, which is implicated in multiple inflammatory and fibrotic processes.*